Ipilimumab in Renal Cell Carcinoma

Drug class Target Agent Diseases Line of Therapy Status Source
CTLA-4 inhibitors, Immunotherapy, Monoclonal antibody CTLA-4 ipilimumab (Yervoy) renal cell carcinoma metastatic FDA Approved Motzer et al. 2018

In a phase III trial, over a thousand renal cell carcinoma patients were randomized to receive nivolumab plus ipilimumab followed by nivolumab or sunitinib. In the intermediate- and poor-risk patients, overall survival was significantly higher with the combination therapy of nivolumab plus ipilimumab (Motzer et al. 2018). Ipilimumab was approved in combination with nivolumab for the treatment of patients with intermediate and poor risk renal cell carcinoma in 2018 (FDA 2018).

Reference Study Type / Phase Line of Treatment Treatment Agent Patient cohort # Patients in Study Response Rate PFS (months) OS (months)
Motzer et al. 2018 Phase III 1st line nivolumab + ipilimumab Intermediate- and Poor-Risk Patients 425 42% 11.6 not reached
sunitinib Intermediate- and Poor-Risk Patients 422 27% 8.4 26
NOTE: OS = overall survival; PFS = progression-free survival

Last Updated: May 24, 2018

Disclaimer: The information presented at padiracinnovation.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.